Recently, Xu and colleagues [12] demonstrated that the use of TERT promoter mutation and ONECUT2 methylation as epigenetic biomarkers showed superior performance in the detection of UTUC (sensitivity of 94.0%, specificity of 93.1%). This evidence concerns the gene TERT and renal pelvis/ureter urothelial carcinoma.